Violet Therapeutics Raises $4.75M in Seed Extension Funding

The company plans to use the funding to advance its lead small-molecule program targeting EphB3 and to support important IND-enabling development activities.

Violet Therapeutics is a preclinical-stage biotech company developing new treatments for neurodegenerative diseases. The company studies how brain cells communicate to understand better the causes of neuroinflammation, neurodegeneration, and synaptic loss. Its proprietary CONNECT platform is designed to identify key signaling pathways in the brain that could serve as targets for future therapies.

Synaptic loss is one of the main drivers of cognitive decline in Alzheimer’s disease and other neurodegenerative conditions. Violet Therapeutics’s lead program aims to address this by focusing on glial mediated synaptic preservation, and repair.

“Preserving cognitive function is one of the most important challenges in aging biology, and Violet is approaching that challenge from a uniquely actionable angle,” said Altar Munis, Associate at Lifespan Vision Ventures. The company’s CONNECT platform helps identify how glial signaling contributes to synaptic dysfunction, with EphB3 identified as an important first step toward potential brain-protective therapies.

Read More:Limbach Appointment of Michael Reed as Chief Operating Officer

"We are pleased to welcome LVV as the lead investor in this extension round. LVV brings deep sector expertise in technologies that will impact diseases of aging and cognition. Likewise, their addition to the board adds valuable perspective as we continue to advance our EphB3 program towards the clinic and to develop our CONNECT discovery platform," said Meredith Fisher, Partner at Mass General Brigham Ventures and CEO of Violet.

About Violet Therapeutics

Founded by Kevin Hodgetts, Violet Therapeutics is a preclinical-stage biotech company developing new therapies for neurodegenerative diseases. The company studies how brain cells communicate to identify disease-related signaling pathways. Its proprietary CONNECT platform identifies new drug targets from cell interaction networks, supporting the development of small-molecule treatments for neuroinflammation and other CNS diseases.

Read More:Kin Health Raises $9M in seed round led by Maveron